Compare Becton Dickinson and Co (BDX) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $59.01 (market cap $75.48B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is the larger of the two by market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays the higher dividend (3.4%). Which is the better fit depends on your goals.
| BDX | MDLZ | |
|---|---|---|
Market Cap | $41.51B | $75.48B |
Sector | Health | Consumer Staples |
52-Week High | $185.39 | $70.75 |
52-Week Low | $135.49 | $51.51 |
Enterprise Value | $57.97B | $95.58B |
Dividend Yield | 2.79% | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
MDLZ trades at $59.86, up 1.75% today, with a neutral technical signal and bullish moving averages. Revenue grew to $38.54B in 2025, though net income fell to $2.45B. The company maintains strong brand innovation with recent product launches and a new CFO appointment. Analysts show strong buy sentiment with a $68.00 consensus target, implying 13.6% upside.
Outlook remains positive driven by consistent earnings beats and brand strength, but risks include margin pressure from input costs and competitive headwinds. The stock offers a balanced opportunity for growth investors seeking stable consumer staples exposure with dividend income.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
